Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.

de Vos S, Wagner-Johnston ND, Coutre SE, Flinn IW, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Kim Y, Godfrey WR, Leonard JP.

Blood Adv. 2016 Nov 30;1(2):122-131. doi: 10.1182/bloodadvances.2016000976. eCollection 2016 Dec 13.

2.

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND.

Blood. 2014 May 29;123(22):3398-405. doi: 10.1182/blood-2013-11-537555. Epub 2014 Mar 10.

3.

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE.

Blood. 2014 May 29;123(22):3406-13. doi: 10.1182/blood-2013-11-538546. Epub 2014 Mar 10.

4.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA.

N Engl J Med. 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22.

5.

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.

J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.

6.

NF90 regulates inducible IL-2 gene expression in T cells.

Shi L, Godfrey WR, Lin J, Zhao G, Kao PN.

J Exp Med. 2007 May 14;204(5):971-7. Epub 2007 Apr 30.

7.

CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy.

Li L, Godfrey WR, Porter SB, Ge Y, June CH, Blazar BR, Boussiotis VA.

Blood. 2005 Nov 1;106(9):3068-73. Epub 2005 Jul 14.

8.

NF90 regulates cell cycle exit and terminal myogenic differentiation by direct binding to the 3'-untranslated region of MyoD and p21WAF1/CIP1 mRNAs.

Shi L, Zhao G, Qiu D, Godfrey WR, Vogel H, Rando TA, Hu H, Kao PN.

J Biol Chem. 2005 May 13;280(19):18981-9. Epub 2005 Mar 3.

9.

Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function.

Godfrey WR, Spoden DJ, Ge YG, Baker SR, Liu B, Levine BL, June CH, Blazar BR, Porter SB.

Blood. 2005 Jan 15;105(2):750-8. Epub 2004 Sep 16.

10.

In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures.

Godfrey WR, Ge YG, Spoden DJ, Levine BL, June CH, Blazar BR, Porter SB.

Blood. 2004 Jul 15;104(2):453-61. Epub 2004 Mar 18.

11.

Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation.

Godfrey WR, Krampf MR, Taylor PA, Blazar BR.

Blood. 2004 Feb 1;103(3):1158-65. Epub 2003 Oct 2.

12.

Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40).

Pippig SD, Peña-Rossi C, Long J, Godfrey WR, Fowell DJ, Reiner SL, Birkeland ML, Locksley RM, Barclay AN, Killeen N.

J Immunol. 1999 Dec 15;163(12):6520-9.

13.

Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells.

Fagnoni FF, Takamizawa M, Godfrey WR, Rivas A, Azuma M, Okumura K, Engleman EG.

Immunology. 1995 Jul;85(3):467-74.

14.

Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor.

Godfrey WR, Fagnoni FF, Harara MA, Buck D, Engleman EG.

J Exp Med. 1994 Aug 1;180(2):757-62.

15.

Preliminary communication: evaluation of potassium-rich electrolyte solutions as oral prophylaxis for heat stress disease.

Schamadan JL, Godfrey WR, Snively WD Jr.

IMS Ind Med Surg. 1968 Sep;37(9):677-84. No abstract available.

PMID:
5246027

Supplemental Content

Loading ...
Support Center